Nachrichten zur Novo-Nordisk AS Aktie

Rolls-Royce topped European stocks in 2023

UK engine maker’s performance on Stoxx 600 comfortably beats Danish pharma giant Novo Nordisk…

Gubra-CFO Kristian Borbos: "Die Entdeckung und Entwicklung von Adipositas-Therapien sind eine ...

Novo Nordisk hat im Jahr 2023 nicht nur sein 100-jähriges Bestehen gefeiert, sondern ist auch zum wertvollsten börsennotierten europäischen Unternehmen…

Novo Nordisk: Massive Produktionserweiterungspläne - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Novo Nordisk-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Novo Nordisk A/S…

These 3 Companies Can Be the Next Stock-Split Stocks in 2024 @themotleyfool #stocks $AVGO $CMG $COST $GOOGL $TSLA $AMZN $NVDA $MNST $NVO $PANW $GOOG $SHOP $DXCM

Since mid-2021, Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk have conducted stock splits.…

These 3 Companies Can Be the Next Stock-Split Stocks in 2024

Since mid-2021, Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk have conducted stock splits.…

Interested in the Weight-Loss Market? Heres 1 Stock to Buy Hand Over Fist in 2024, and 1 to Avoid Like the Plague.

While Novo Nordisk dominates the weight-loss market, there are two other stocks to consider as well.…

The Zacks Analyst Blog Highlights Novo Nordisk, Walmart, Advanced Micro Devices, Caterpillar and Union Pacific

Novo Nordisk, Walmart, Advanced Micro Devices, Caterpillar and Union Pacific are part of the Zacks top Analyst Blog.…

Meet the Stock-Split Stock Warren Buffett Is Likeliest to Buy in 2024

Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, theres a stock-split stock that…

Meet the Stock-Split Stock Warren Buffett Is Likeliest to Buy in 2024 @themotleyfool #stocks $GOOGL $BRK.A $BRK.B $AMZN $TSLA $NVDA $MNST $NVO $PANW $GOOG $SHOP $DXCM

Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, theres a stock-split stock that…

Top Analyst Reports for Novo Nordisk, Walmart & AMD

Todays Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Walmart Inc. (WMT) and…

3 Stock-Split Stocks Billionaires Are Piling Into Ahead of 2024

Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three industry leaders…

3 Stock-Split Stocks Billionaires Are Piling Into Ahead of 2024 @themotleyfool #stocks $AMZN $GOOGL $TSLA $NVDA $MNST $NVO $PANW $GOOG $SHOP $DXCM

Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three industry leaders…

Novo Nordisk, FDA warn of fake Ozempic

The FDA has seized thousands of units of fake Ozempic, the agency said Thursday.…

Novo Nordisk 2023: Beeindruckende 42 Prozent Aktienwachstum

Das Jahr 2023 markierte für Novo Nordisk einen Wendepunkt, geprägt von signifikanten Entwicklungen sowohl in der Unternehmensleistung als auch in…

Global Injection Pen Market Analysis and Forecast to 2028, Featuring Analysis of Key Players Sanofi, Eli Lilly, Novo Nordisk, Becton Dickinson, AstraZeneca, F. Hoffmann-La Roche & Merck

Dublin, Dec. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Injection Pen Market: Analysis By Type, By Therapy, By…

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 22 December 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with…

Novo Nordisk: Kampfansage gegen Eli Lilly

Novo Nordisk reagiert auf Konkurrenz von Eli Lilly im Abnehmpräparatemarkt mit neuem Präparat CagriSema, das eine vergleichbare Wirksamkeit verspricht.…

Novo Nordisk: Weitere Entwicklungen rund um CagriSema mit Argusaugen verfolgen! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Novo Nordisk-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Novo Nordisk A/S…

Health Stocks Get Shot at Redemption After Ozempic-Fueled Losses

Few on Wall Street predicted that the frenzy for weight-loss treatments would supercharge Eli Lilly & Co. and Novo Nordisk…

Gesucht wird die neue Apple, Nvidia oder Novo Nordisk – das sind die großen AKTIONÄR-Favoriten für 2024

Auf der Zielgeraden hat sich dieses Börsenjahr im Hinblick auf den DAX tatsächlich noch von einem guten zu einem sensationellen…

New weight-loss-drug rivals to Eli Lilly and Novo Nordisk in 2024?

…

Five obesity-drug trends to watch in 2024: Who can compete with Eli Lilly and Novo Nordisk?

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and…

These 2 Unstoppable Stocks Could Make You Richer in 2024 and Beyond

Eli Lilly and Novo Nordisk are disrupting the weight-loss market with treatments like Mounjaro and Ozempic.…

4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow

Novo Nordisk (NVO), Journey Medical Corporation (DERM), Lyra Therapeutics (LYRA) and Fusion Pharmaceuticals (FUSN) have returned 40% or higher year…

Novo Nordisk Stock Frenzy Can’t Stop Denmark From Lagging Europe

Blockbuster obesity drug maker Novo Nordisk A/S became more valuable than Denmark’s economy in 2023, but that wasn’t enough to…

Alexandria (ARE) Inks Leases at its Campuses Amid Solid Demand

Amid the booming demand for life-science assets, Alexandria (ARE) inks leases with Novo Nordisk and CARGO at its mega campuses…

Aktien News: Einblicke in Novo Nordisks jüngste Marktbewegungen Dezember 2023

Die Aktien von Novo Nordisk A/S (NVO) haben in letzter Zeit signifikante Schwankungen erlebt. Eine wesentliche Ursache für diese Volatilität…

Why Novo Nordisk Stock Is Moving Higher Today

An Indian e-commerce company is helping Novo Nordisk combat illegal sales of weight loss drug Wegovy.…

Novo Nordisk: Doppelte Kaufempfehlung - AKTIONÄR-Dauerbrenner über 500 Prozent im Plus

Unter den europäischen Large Caps gehört im Kalenderjahr 2023 das Papier von Novo Nordisk zweifelsohne zu den absoluten Überfliegern. Allein…

Novo Nordisk: Doppelte Kaufempfehlung – AKTIONÄR-Dauerbrenner über 500 Prozent im Plus

Unter den europäischen Large Caps gehört im Kalenderjahr 2023 das Papier von Novo Nordisk zweifelsohne zu den absoluten Überfliegern. Allein…

Novo Nordisk: Weiteres Aufwärtspotenzial - Aktienanalyse

Kulmbach (www.aktiencheck.de) - Novo Nordisk-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Aktie…

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 18 December 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with…

Novo Nordisk owner channels some of Wegovy windfall into respiratory diseases

The Novo Nordisk (NYSE:NVO) Foundation, which has the controlling holding of Novo Nordisk (NYSE:NVO), has announced an investment of around $265…

Fake Wegovy: Pharma Giant Novo Nordisk Reportedly Steps Up Efforts Tackling Illegal Weight Loss Drugs Sold Online

Novo Nordisk is reportedly working with a leading Indian online marketplace to tackle illegal sales of popular weight loss drug…

3 Stock-Split Stocks With 51% to 128% Upside in 2024, According to Select Wall Street Analysts

Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three high-flying stocks…

3 Stock-Split Stocks With 51% to 128% Upside in 2024, According to Select Wall Street Analysts @themotleyfool #stocks $NVDA $INTC $AMZN $TSLA $GOOGL $AMD $MNST $NVO $PANW $GOOG $SHOP $DXCM

Among Nvidia, Amazon, DexCom, Shopify, Alphabet, Tesla, Palo Alto Networks, Monster Beverage, and Novo Nordisk, there are three high-flying stocks…

Ozempic Isnt the Best Weight-Loss Treatment Anymore. Heres Why That Shouldnt Matter to Novo Nordisk Investors. @themotleyfool #stocks $NVO $LLY

Investors shouldnt be quick to discount Novo Nordisks long-term potential.…

Ozempic Isnt the Best Weight-Loss Treatment Anymore. Heres Why That Shouldnt Matter to Novo Nordisk Investors.

Investors shouldnt be quick to discount Novo Nordisks long-term potential.…

dpa-AFX ProFeed